GlassScriptPhysician profile
Joshua E Lowentritt
NPI 1235180266
$6,966.91
in general payments reported to CMS, 2019-2025
26 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $24.10 · 2021: $19.90 · 2022: $208 · 2023: $710 · 2024: $4,291 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,400 · Travel and Lodging: $681 · Education: $28.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,040.40 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,400.00 |
| Travel and Lodging | $681.31 |
| Education | $28.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $3,890.00 | 2024-2025 | Optiflux, Crit-Line |
| Bayer Healthcare Pharmaceuticals INC. | $412.48 | 2022-2025 | |
| Corcept Therapeutics | $391.17 | 2024-2025 | Korlym |
| Amgen INC. | $312.80 | 2019-2024 | Tavneos, Repatha, Prolia |
| Novo Nordisk INC | $229.46 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $215.03 | 2019-2025 | Farxiga |
| Aurinia Pharma U.S., INC. | $210.73 | 2022-2025 | Lupkynis |
| Akebia Therapeutics INC | $201.62 | 2019-2025 | Vafseo |
| Idorsia Pharmaceuticals US INC | $136.74 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.43 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $129.43 | 2025 | |
| Baxter Healthcare | $114.39 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $97.43 | 2022-2025 | Jynarque, Voyxact |
| Nxstage Medical, INC. | $73.16 | 2019 | |
| Shire North American Group INC | $71.73 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $61.28 | 2023-2025 | Tarpeyo |
| Pfizer INC. | $57.30 | 2019-2020 | |
| Abbvie INC. | $55.56 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $32.32 | 2019 | |
| Mallinckrodt Hospital Products INC. | $27.94 | 2025 | Acthar |
| Amryt Pharma Holdings LTD | $27.71 | 2023 | Mycapssa |
| Merck Sharp & Dohme LLC | $24.89 | 2019-2020 | |
| Lilly USA, LLC | $23.96 | 2024 | Jardiance |
| Seqirus USA INC | $13.73 | 2019 | |
| Vifor Pharma, INC. | $12.95 | 2019 | |
| Genentech USA, INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Lowentritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.